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ABSTRACT  
 
Poly-lactide-co-glycolide (PLGA) microparticles emerged as one of the most promising 
strategies to achieve site-specific drug delivery. Although these microparticles have 
been demonstrated to be effective in several wound healing models, their potential in 
cardiac regeneration has not yet been fully assessed. The present work sought to explore 
PLGA microparticles as cardiac drug delivery systems. PLGA microparticles were 
prepared by Total Recirculation One-Machine System (TROMS) after the formation of 
a multiple emulsion. Microparticles of different size were prepared and characterized to 
select the most suitable size for intramyocardial administration. Next, the potential of 
PLGA microparticles for administration in the heart was assessed in a MI rat model. 
Particle biodegradation over time and myocardial tissue reaction were studied by 
routine staining and confocal microscopy. Results showed that microparticles with a 
diameter of 5 µm were the most compatible with intramyocardial administration in 
terms of injectability through a 29-gauge needle and tissue response. Particles were 
present in the heart tissue for up to three months post-implantation and no particle 
migration towards other solid organs was observed, demonstrating good myocardial 
retention. CD68 immunolabeling revealed 31%, 47% and below 4% microparticle 
uptake by macrophages one week, one month and three months after injection, 
respectively (P<0.001). Taken together, these findings support the feasibility of the 
developed PLGA microparticles as vehicles for delivering growth factors in the 
infarcted myocardium.  
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1. Introduction 
 
 Myocardial infarction (MI) is a great threat to life in developed countries, and so 
research efforts are being focused on the development of new therapies. Therapeutic 
angiogenesis induced by exogenous administration of growth factors such as vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) has been 
considered a promising strategy to treat patients with MI. However, although many pre-
clinical studies have reported beneficial effects of angiogenic growth factor 
administration after MI, neither VEGF nor FGF have demonstrated efficacy in double-
blinded clinical trials [1, 2]. These disappointing results were attributed, at least 
partially, to the high intrinsic instability of the protein when systemically administered 
and the short half-life during which growth factors retain their biologic activity in vivo. 
 Current methods for growth factor delivery require administration of high 
protein concentration and repeated injections, which may result in abnormal vessel 
formation and unwanted side effects such as hypotension [3, 4]. Targeted delivery of 
angiogenic proteins into the ischemic heart could therefore be useful. Delivery strategies 
that provide sustained local release of growth factors would not only control protein 
concentration, but could also minimize systemic exposure. A number of approaches 
have been designed to deliver growth factors in the heart in a controlled fashion. These 
include hydrogels, peptide nanofibers, liposomes, nano- and microparticles mainly for 
delivery of VEGF [5-9], FGF-1 [10] and FGF-2 [11, 12]. While each delivery platform 
has both merits and drawbacks in the controlled delivery of angiogenic growth factors, 
there are few reports about the feasibility of these approaches via the intramyocardial 
route in relation to injectability, local retention and tissue response.  
 Polymeric microparticles encapsulating protein drugs offer the possibility of 
controlling the release of macromolecules over extended time periods [13]. Copolymers 
of lactic and glycolic acids (PLGAs) have been studied most commonly for this purpose 
because of their proven safety record and established use in marketed products for 
controlled delivery of several peptide drugs [14, 15]. Nevertheless, PLGA 
microparticles have not been thoroughly investigated as a feasible delivery system for 
growth factors into the myocardium.     
 In this study, the compatibility of PLGA microparticles with intramyocardial 
administration was evaluated in a rat model of myocardial ischemia. To this end, PLGA 
microparticles were prepared using Total Recirculation One-Machine System 
(TROMS), a technique based on the multiple emulsion solvent evaporation method 
which is suitable for the encapsulation of labile molecules like proteins [7, 16]. Physical 
characteristics of the microparticles such as morphology, size or surface charge were 
primarily investigated. Furthermore, flow properties such as dispersability and 
injectability of microparticle suspension were analyzed to avoid complications during 
their administration. The in vivo biodegradation of the particles in the infarcted tissue 
and the evaluation of the myocardial responses to PLGA microparticles were finally 
evaluated using a rat model of MI to ensure safety and biocompatibility requirements. 
 
2. Materials and Methods  
 
2.1 Materials 
 PLGA with a monomer ratio (lactic acid/ glycolic acid) of 50:50 Resomer® RG 
503H (Mw: 34 kDa) was provided by Boehringer-Ingelheim (Ingelheim, Germany). 
Polyethylene glycol (PEG; Mw: 400), human serum albumin (HSA) and rhodamine B 
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isothiocyanate were provided by Sigma-Aldrich (Barcelona, Spain). Dichloromethane 
and acetone were obtained from Panreac Quimica S.A. (Barcelona, Spain). Poly(vinyl 
alcohol) (PVA) 88% hydrolyzed (Mw: 125,000) was obtained from Polysciences, Inc. 
(Warrington, PA, USA). Dubelcco’s Modified Eagle Medium (DMEM) was provided 
from Gibco-Invitrogen (Carlsbad, CA, USA). Mouse monoclonal anti-rat CD68 
antibody (MCA341R) was purchased from Serotec (Oxford, UK). Alexa Fluor 488 goat 
anti–mouse IgG antibody was provided by from Molecular Probes (Eugene, OR, USA). 
 
2.3 Microparticle preparation 
 PLGA microparticles were obtained after the preparation of a multiple emulsion 
by solvent evaporation method using the Total Recirculation One-Machine System 
(TROMS) [7, 16, 17]. Briefly, the organic phase (O) composed of 50 mg of PLGA 
dissolved in 2 ml of a dichloromethane/acetone mixture (ratio 3:1) was injected into the 
inner aqueous phase (W1) containing 5 mg of HSA and 5 μl of PEG 400 dissolved in 
200 μl of phosphate-buffered saline (PBS pH 7.9). Next, the previously formed inner 
emulsion (W1/O) was recirculated through the system under a turbulent regime 
maintained by a pumping flow through a needle with an inner diameter of 0.17 mm. 
After this homogenization step, the W1/O emulsion was injected into the outer aqueous 
phase (W2) composed of 20 ml of a 0.5%w/v PVA solution. The turbulent injection 
through a second needle resulted in the formation of a multiple emulsion (W1/O/W2), 
which was allowed to circulate through the system to become homogeneous. The 
multiple emulsion was stirred for 3 h to allow solvent evaporation. Microparticles were 
washed three times with ultrapure water by consecutive centrifugation at 4 °C 
(20,000×g, 10 min). Finally, the particles were resuspended in 1 ml of ultrapure water, 
frozen at −80 °C, lyophilized (Genesis 12EL, Virtis) and stored at 4 °C. In order to 
obtain batches with different particle sizes, the following TROMS parameters were 
adjusted during microparticle preparation: pumping flow, recirculation times to form 
W1/O and W1/O/W2 emulsions, and the inner diameter of the needle used to prepare the 
W1/O/W2 emulsion. A needle with an inner diameter of 0.17 mm was used to form the 
primary W1/O emulsion of all microparticle batches.  
For fluorescence-labeled microparticle formulation, rhodamine B isothiocyanate (0.5 
mg/mL) was added to the inner aqueous phase and microparticles were prepared as 
described. 
 
2.4 Size, surface charge analysis and morphological observation of PLGA 
microparticles 
 Particle size and size distribution of the microparticles were measured by laser 
diffractometry using a Mastersizer® (Malvern Instruments, UK). The average particle 
size was expressed as the volume mean diameter in micrometers and samples were 
measured in triplicate. 
 For rhodamine-labeled microparticles, particle size was estimated using the 
software imaging system Cell* connected to the camera fluorescence microscopy 
system CH40 (Olympus GmbH, Münster, Germany). The morphology of the particles 
was characterized by scanning electron microscopy (SEM). Briefly, the lyophilized 
microparticles were mounted on carbon conductive disks attached to aluminum stubs. 
Samples were then coated with gold to a 16-mm thickness (Emitech K550 equipment). 
Microparticles were randomly scanned using SEM (Zeiss DSM 940A, Germany) and 
photomicrographs were taken.  
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 Particle surface charge was determined by zeta potential measurement (Zeta Plus 
Potential Analyzer, Brookhaven Instruments Corp., New York, USA). A dilute 
suspension (0.5 mg/ml) of microparticles was prepared in 1 mM KCl (pH = 7.6) and the 
zeta potential measurements were performed after 10 cycles in the high precision mode. 
 Rhodamine-labeled microparticles were imaged at high-power by fluorescence 
microscopy. Microparticles were resuspended in water, mounted on a microscope slide, 
and visualized using a camera microscopy system (Olympus CH40). 
 
2.5 Determination of microparticle dispersability and injectability  
 Prior to in vivo studies, microparticle dispersability was tested in three different 
resuspension media: PBS, DMEM and DMEM supplemented with a surfactant mixture 
composed of 0.1%w/v carboxymethyl cellulose, 0.8% w/v, polysorbate 80 and 0.8% w/v 
mannitol in PBS, pH 7.4 (DMEM-S). Microparticle suspension injectability was 
assessed by its ability to pass through a 29-gauge needle, since these needles are used 
for heart injection [11]. Particle concentration and particle size were evaluated as 
injectability parameters in order to define the optimal microparticle formulation for 
heart injection. 
 
2.6 Quantification of residual PVA content 
 The residual PVA associated with microparticles was determined by a 
colorimetric method [18]. Two milligrams of dry microparticles were hydrolyzed with 2 
ml of 0.5 M NaOH for 15 min at 60ºC. The solution was then neutralized with 900 µl of 
1 N HCl and the volume was adjusted to 5 ml with distilled water. Next, 3 ml of a 0.65 
M solution of boric acid, 0.5 ml of a solution of I2/KI (0.05 M/0.15 M) and 1.5 ml of 
distilled water were added. These conditions allowed the formation of a colored 
complex between two adjacent hydroxyl groups of PVA and an iodine molecule. After 
15 min of incubation, the absorbance was measured at 690 nm using an Agilent 8453 
UV–visible spectrophotometer (Agilent technologies, Palo Alto, CA, USA). A standard 
plot of PVA was prepared under identical conditions and measurements were performed 
in triplicate. 
 
2.7 In vivo studies using PLGA microparticles 
 
2.7.1 Induction of myocardial infarction 
 All animal procedures were approved by the University of Navarra Institutional 
Committee on Care and Use of Laboratory Animals as well as the European 
Community Council Directive Ref. 2010/63/EU. Animal experiments were carried out 
using a rat model of cardiac acute ischemia-reperfusion. Rats were initially anesthetized 
with 4% isoflurane in an induction chamber. Prior to surgery, animals received 
analgesic drug ketoprofen 5 mg/kg subcutaneously, fentanyl 0.15 mg/kg and heparin 0.1 
mg/kg both administered by intraperitoneal route. The rats were then intubated and 
ventilated at 90 cycles/min (1.5–2% isoflurane was maintained for continuous 
anesthesia). A left thoracotomy through the fourth intercostal space was performed, and 
the left anterior descending (LAD) coronary artery was occluded 2–3 mm distal from its 
origin for 1 h and then re-opened. The chest was then closed in layers and rats allowed 
to recover on a heating pad.  
 
2.7.2 Intramyocardial administration of microparticles 
 Four days after LAD coronary artery occlusion, animals were assigned to 
receive microparticles of different sizes (2, 5, 14 and 30 μm) or medium alone. 
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Microparticle suspensions (2 mg/100 µl) were injected with a 29-gauge needle into 4 
regions of the border zone surrounding the infarct while the heart was beating. A total of 
22 animals were used in the in vivo experiments. The chest was closed and rats were 
allowed to recover on a heated pad.  
 
2.7.3 Histological assessment of myocardial tissue after microparticle administration 
 Animals were sacrificed at different times after microparticle injection and their 
hearts were collected for histology. After being harvested, the hearts were perfused-
fixed in 4% paraformaldehyde at 4 °C, and sliced in three 4-mm-thick segments from 
apex to base. The hearts were dehydrated in ethanol 70% at 4 °C, embedded in paraffin 
and cut 5-μm-sections. Hematoxylin–eosin (HE) staining was carried out to localize the 
microparticles and to visualize tissue structure. Samples from control zone (non-injected 
tissue), right ventricle, and other organs (kidney, liver and spleen) were also analyzed.  
 
2.7.4 In vivo biodegradation, tissue retention and phagocytic uptake of microparticles 
 A group of infarcted animals (n=8) was injected four days after LAD coronary 
artery occlusion with 5 μm-sized fluorescence-labeled microparticles and sacrificed 8, 
30 and 90 days later. Rhodamine B was used as a fluorescent marker to localize the 
injected microparticles by confocal microscopy in the heart tissue. After the hearts were 
frozen in OTC compound, frozen sections were prepared. In order to assess the 
phagocytic uptake of microparticles after their intramyocardial delivery, rat macrophage 
staining was carried out. CD68 immunofluorescence was performed as follows: slides 
were dried for 15 min at room temperature. Next, tissue sections were hydrated by 
passing through a graded ethanol series for 2 min each from absolute ethanol, 96%, 
80%, and 70% followed by washing in running tap water, and subsequently in distilled 
water. Prior to blocking with 5% bovine serum albumin (BSA) for 30 min, sections 
were rinsed with Tris Buffered Saline (TBS) plus 0.05% Tween 20 (TBST). Labelling 
with primary antibody was performed using a mouse anti-rat CD68 antibody (diluted 
1:100 in TBS) by incubating at 4 ºC overnight. After three consecutive washings with 
TBST (5 min each), fluorescent Alexa Fluor 488 goat anti–mouse IgG secondary 
antibody (1:100 dilution) was applied to sections for 1 h in the dark followed by nucleus 
staining with TOPRO-3 (diluted 1:50 in PBS-glycerol). For confocal microscopy, a 
LSM 510 META (Carl Zeiss, Minneapolis, USA) microscope was used. Digital images 
at 40× were analyzed in order to quantify the cardiac phagocytic uptake of injected 
microparticles. The extent of phagocytosis was expressed in terms of microparticle 
phagocytosis index determined as the ratio between the number of rhodamine-loaded 
microparticles internalized in CD68-positive macrophages and the total number of 
microparticles detected in each section. Eight serial sections of each rat were analyzed.  
 
2.7.5 Statistical analysis 
Data are presented as mean ± S.D. Statistics was calculated with Prism 5.0 software 
(Graphpad Software Inc., San Diego, CA, USA). The differences among mp batches or 
groups of animals were first evaluated using the Kruskal–Wallis Test, followed by 
Mann–Whitney U-test when values followed a non-parametric distribution. The 
differences among the batches of microparticles or the groups of animals were assessed 
by ANOVA with a Tukey post hoc correction when the measured values were normally 
distributed. Shapiro–Wilk test was used to justify the use of a parametric test. A value 
of P<0.05 was considered statistically significant. 
 
3. Results and discussion 
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3.1 PLGA microparticles prepared by TROMS 
 A wide range of formulation methods have been used for encapsulating drugs 
into PLGA microparticles. These include solvent extraction [19], phase separation [20], 
spray drying [21], solid encapsulation [22], static mixer extrusion [23], and expansion in 
a supercritical fluid [24]. But the most frequently utilized method for the entrapment of 
fragile molecules is the water/oil/water (W/O/W) multiple emulsion solvent evaporation 
method [25]. Based on this method, TROMS has the advantage, over the conventional 
solvent evaporation techniques, of encapsulating compounds without the need for 
aggressive techniques or heating during the emulsification process. Thus, the method is 
especially useful for the encapsulation of fragile molecules such as growth factors. 
Previously, we successfully encapsulated VEGF and GDNF into PLGA-MP using 
TROMS, which maintained their biological activities [7, 16, 26]. In fact, higher 
encapsulation efficiencies were found when using TROMS. For instance, VEGF 
encapsulation efficiency up to 83% were achieved by TROMS [7]. In contrast, Cao et 
al. reported an entrapment efficiency of 14.5% of VEGF in PLGA-MP, employing the 
solid-encapsulation method [27]. In turn, Kim et al. proposed a combination of the 
multiple-emulsion technique and the atomization-freeze process into a unique solid-
encapsulation/single-emulsion/solvent extraction method, but the entrapment efficiency 
of VEGF into PLGA microparticles using this manufacturing strategy was not 
improved, achieving a 16% entrapment efficiency [22]. Furthermore, another significant 
benefit of TROMS in view of its industrial application is the consistent production of 
very homogeneous batches of microparticles allowing for an easy scale-up of the 
manufacturing process.  
 In this study, TROMS produced microparticles in the size range of 2-30 µm 
varying apparatus conditions during microparticle production. Particle size remained 
unchanged after lyophilization. The needle diameter for W1/O/W2 emulsion formation, 
pumping flow and recirculation times of both W1/O and W1/O/W2 emulsions yielded 
batches with different particle sizes (Table 1). The inner diameter of the needles is a 
critical factor determining the final size of microparticles prepared by TROMS [17]. 
Microparticles with a diameter around 30 µm (batch 1) were obtained using the largest 
needle diameter to form the multiple emulsion (0.50 mm). A significant reduction in 
particle size was observed with needle diameters of 0.25 mm and 0.12 mm (batches 2 
and 3, respectively, compared with batch 1, P<0.01). Table 1 also shows the influence 
of recirculation times of both W1/O and W1/O/W2 emulsions on the final size of 
microparticles, which was strongly dependent on the recirculation time of the primary 
W1/O emulsion. A reduction of 1 min on the recirculation time of this emulsion 
increased significantly the particle size from 4.1 µm (batch 4) to 14.7 µm (batch 5) 
(P<0.01). The pumping flow also played a key role in the final size of the 
microparticles, whereas increasing flows led to more turbulent regimes to form both 
primary and multiple emulsions. Consequently, smaller microparticles were formed 
under higher homogenization energies supplied by more vigorous flows (batches 7 and 
9, P<0.05).  
Colloidal stability was analyzed by measuring the zeta potential of PLGA microparticle 
surface. Particles were negatively charged (around –30 mV at pH 7.6) and no significant 
differences in zeta potential values were observed among all TROMS-produced 
microparticles batches. The morphology of the microparticles was examined by 
fluorescence microscopy (Fig. 1A). Microparticles appeared spherical in shape. Red 
fluorescence was distributed in the polymer matrix, indicating good rhodamine 
encapsulation. SEM visualization of the microparticles confirmed these findings, 
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revealing a spherical shape with a smooth surface and few small pores in some particles 
(Fig. 1B). Physical characteristics of microparticles such as morphology, size or surface 
charge were investigated as well as quality controls for batch-to-batch consistency. 
Concerning the residual PVA content, the percentage of PVA recovered in the 
microparticles ranged from 1.1% to 1.6% depending on the formulations. These values 
are several times lower than 13%w/w PVA content previously reported [28]. The 
differences could be explained by the polarity of organic solvent that was used by 
Zambaux et al., [28] compared to that used in our study (dichloromethane vs. 
dichloromethane-acetone). Probably, the co-solvent system composed by a 
dichloromethane-acetone mixture led to less PVA partitioned into the polymeric phase, 
resulting in the lower deposition of PVA on the surface of TROMS-produced 
microparticles. Residual PVA differences could also be attributed to other formulation 
parameters such as PVA concentration in the external aqueous phase and PVA 
molecular weight. 
 
 
3.2 Dispersability and injectability of microparticle suspension 
 Injectable microparticles encapsulating therapeutic agents require that the 
microparticles be well dispersed in the media used to deliver the agent. Therefore, good 
flow properties of the microparticles are necessary to ensure dose uniformity and safety 
requirements. In the present work, dispersability and injectability of TROMS produced 
microparticles were assessed to select an adequate injectable PLGA microparticle 
suspension for local myocardial injection. These flow properties describe the ability of 
the microparticle suspension to pass easily through a needle. Dispersability of freeze-
dried microparticles was tested in 3 different saline solutions: PBS, DMEM and 
DMEM-S. PBS and DMEM are solutions commonly employed to inject drugs/cells into 
the infarcted heart [29, 30] and the carboxymethyl cellulose solution containing 
polysorbate 80 and mannitol has been previously used to suspend PLGA microparticles 
prior to intracerebral implantation [26]. Carboxymethyl cellulose is a wetting and 
biocompatible agent that prevents particle aggregation and makes easier their injection 
through a thin needle. Furthermore, carboxymethyl cellulose solution is a viscosity 
building agent commonly used in the formulation of oral and injectable pharmaceutical 
suspensions [31, 32]. Microparticles were better dispersed in DMEM-S, probably due to 
the surfactant mixture added to medium, which increased DMEM viscosity and reduced 
particle aggregation and sedimentation. Thus, DMEM supplemented with 
carboxymethylcellulose, polysorbate 80 and mannitol was selected as injection medium 
for animal experiments. Microparticle suspension in the range of 2−5 mg/100 µl was 
found to be both dispersible and injectable. Particle batches of 14 µm and 30 µm 
exhibited some resistance to resuspension in DMEM-S compared to smaller ones, 
probably due to sedimentation of particles with a diameter higher than 14 µm. 
Concerning microparticles’ ability to pass through a 29-gauge needle, a typical needle 
size for heart injection [11], moderate levels of sedimentation could also explain the 
resistance observed when 30 µm-sized particles passed through the needle. In contrast, 
microparticles of 2 µm and 5 µm were flowable. They were easily injected through a 
29-gauge needle. 
 
3.3 Histological evaluation of myocardial tissue after microparticle injection  
 Microparticle batches of 2, 5, 14 and 30 μm were tested according to their 
compatibility with an intramyocardial injection. Microparticles were intramyocardially 
injected in the infarcted beating heart (Fig. 2). As mentioned above, large microparticles 
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did not exhibit suitable resuspension in the injection medium. Indeed, blockages in the 
29-gauge needle were detected during the administration of 30 µm-sized particles in the 
myocardium. Probably, the presence of aggregates obstructed the flow through the 
needle, which limited the injection of large microparticles in the rat heart. Despite the 
obstruction, a residual amount of 30 µm-sized particles reached the infarcted area. HE 
staining showed a more consistent accumulation of inflammation-mediated cells (IMCs) 
after injection of large microparticles (30 μm-injected particles, Fig. 3C and 3D) than in 
smaller ones (2 μm-injected particles, Fig. 3A-B). In fact, it has been described that 
large microparticles (75 μm) caused extensive myocardial necrosis in a porcine model 
[33]. On the other hand, there were fewer IMCs in the surrounding areas of 2 µm-sized 
particles, which did not induce severe responses. However, these 2 μm diameter 
particles exhibited a low retention in the heart, probably due to local phagocytic activity 
(results not shown). Taken together, these observations demonstrated that particles with 
an intermediate diameter could be adequate for heart injection. Consequently, 5 µm-
sized particles were selected for long-term tissue retention and response studies. 
Interestingly, 5 µm-sized particles did not induce inflammatory reactions when 
compared to the injection of resuspension medium. The response of the heart was the 
typical reaction observed following mechanical trauma and exposure to a foreign body. 
Slightly inflamed areas provoked by the needle during the myocardial administration of 
DMEM-S or suspension of microparticles with 5 μm diameter were observed. This 
finding correlates with the report that 7 µm resin particles encapsulating FGF-2 did not 
cause myocardial damage [34]. However, the clinical application of these microparticles 
is limited because the resin material is non-biodegradable, unlike PLGA which degrades 
generating monomeric acids (lactic and glycolic acids) that are consequently eliminated 
from the body as carbon dioxide and water [35]. Importantly, no myocardial 
hemorrhage was observed in our HE sections. Additionally, no signs of physiological 
disturbances such as fibrillation upon microparticles injection and no adverse cellular 
reactions in the tissue adjacent to the implanted microparticles were observed.  
 
3.4 Biodegradation, tissue retention and phagocytic uptake of microparticles in the 
infarcted heart 
Confocal microscopy and HE staining were carried out to study biodegradation of 5 
µm-sized particles over time. The results are illustrated in Fig. 4. Fluorescent 
microparticles were always grouped at the implantation site and they remained at the 
site of injection during the entire 90-day experiment. At the beginning of the study 
microparticles showed a spherical shape but they underwent progressive changes in size 
and morphology over time. Between the first and second week there was a decrease in 
the microsphere size that continued to diminish, at a lower rate, over time. Most of the 
microparticles lost their spherical shape and showed a reduction of their size two 
months after implantation. Importantly, three months after implantation microparticles 
were not totally biodegraded and a significant amount of them were still detectable (Fig. 
4D and 4E). 
 
Some studies have demonstrated a rapid loss of intramyocardially implanted cells or 
drugs which is biologically caused by the contracting myocardium [36, 37]. In the 
present paper we have demonstrated that microparticles were not rapidly washed out 
from the infarcted myocardium (Fig. 2). Immediately after microparticle administration, 
a persistent blanching surrounding the injection point and a change of tissue color from 
dark pink to light pink after polymer injection was observed. There was no 
microparticle loss or leakage during the intramyocardial implantation, indicating a 
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localized retention of the microparticle suspension in the epicardial zone. Confocal 
microscopy and HE staining was performed to evaluate the temporal retention of 
fluorescence labeled PLGA microparticles in the heart tissue. Fluorescent microparticles 
were found in the injection sites up to three months post-implantation (Fig. 4). Whereas 
Sy et al. reported retention of 20 µm-sized poly(cyclohexane-1,4diyl acetone 
dimethylene ketal) (PCADK) microparticles for up to 10 days in the myocardium [38], 
and another study carried out by our group showed retention of 5 µm-sized PLGA 
microparticles encapsulating VEGF for at least 30 days [7], the results of the present 
study showed retention of 5 µm-sized PLGA particles for up to 90 days. These tissue 
retention results indicate the capacity of PLGA microparticles to remain in the 
myocardium for a prolonged period of time, a requirement for sustained growth factor 
treatment. Correlating with histological observations of HE stained sections, no 
fluorescent signal of rhodamine-loaded microparticles was observed in other tissues 
such as kidney, liver and spleen, indicating no migration of the microparticles towards 
solid organs. This is an important feature of PLGA microparticles for local delivery of 
therapeutics into myocardium, preventing systemic side effects of the loaded drugs.    
 
 While there are reports that have described the phagocytic uptake of PLGA 
microparticles in macrophage cultures [39, 40], there is no detailed in vivo study on the 
macrophage-mediated phagocytosis of PLGA microparticles in the heart tissue. As the 
macrophage is a primary responder cell involved in the regulation of post-MI wound 
healing, eliminating apoptotic/necrotic myocytes and other debris [41], phagocytic 
activity of cardiac macrophages upon injected microparticles was further assessed. 
Quantification of phagocytic uptake of rhodamine-loaded microparticles was carried out 
by detection of CD68 macrophages. The extent of phagocytosis measured as the ratio 
between rhodamine-loaded microparticles internalized into CD68-positive macrophages 
and the total number of microparticles detected in each section was assessed in three 
groups of animals: rats sacrificed one week, one month and three months after 
intramyocardial administration of fluorescent microparticles. CD68 immunolabeling 
revealed a microparticle uptake of 31% one week after microparticle injection (Fig. 5A, 
D). An increase in the phagocytic activity of macrophages upon microparticles was 
detected one month after drug administration, with a microparticle phagocytosis index 
of 47% (Fig. 5B, D). In contrast, a very low microparticle uptake (below 4%) was found 
three months after implantation (Fig. 5C, D). 
 In rodent models of MI, within the first hours to 1 day, there are robust up-
regulations of intramyocardial cytokines including tumor necrosis factor-α (TNF-α), 
interleukin-1β (IL-1β), and interleukin-6 (IL-6). These cytokines mediate the acute 
remodeling process in the infarcted myocardium, which includes modulation of cardiac 
macrophages and phagocytosis [42]. After the initial increase of gene expression in the 
infarcted region, the cytokines normally begin to decrease toward baseline after 1 week 
[43]. Therefore, a decrease in the phagocytic uptake of microparticles 1 month after 
injection must be expected, because of decreased phagocytic activity of cardiac 
macrophages during the chronic remodeling post-MI. However, a larger number of 
microparticles internalized into CD68-positive macrophage was quantified in injected 
animals after 1 month compared with 1 week. One potential explanation is that 
microparticles maintained their spherical shape and diameter around 5 µm, presenting 
some resistance to phagocytosis one week after injection, a very short period for 
polymer degradation. In contrast, one month after their injection, particles originally 5 
µm in size were observed as smaller ones (< 2 µm) due to higher polymer degradation. 
Consequently, these small particles in the heart tissue were more susceptible to 
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phagocytosis, whereas particle size around 1 µm is suitable for efficient uptake by 
macrophages [44]. Three months after microparticle injection, microparticles were 
visible in heart tissue. However, a low colocalization degree of microparticles with 
CD68-positive macrophage was observed. It is possible that macrophage response 
decreases considerably after this period, owing to very low levels of intramyocardial 
cytokines which modulate macrophage activation. At this time, damage due to the 
injection is repaired and the inflammatory response is ended. 
   
 On the other hand, in addition to particle size, other formulation parameters 
could affect the phagocytic uptake of microparticles. For example, particle 
hydrophobicity decreases with the amount of residual PVA associated with 
microparticles, reducing their recognition by macrophages [18]. We used a 0.5% PVA 
solution as stabilizer, which prevents microparticle aggregation during solvent removal. 
Using this PVA concentration, microparticles with a minimal content of residual PVA 
were obtained. Moreover, microparticles presented a high negative charge, which is 
associated with a stable colloid nature. An increase in PVA concentration used for 
microparticle formulation would result in the increase in the residual PVA content. 
However, as PVA is a potentially toxic non-biodegradable polymer, its administration 
should be minimized as much as possible [45]. Therefore, changes in formulation 
parameters must be rationally performed to alter microparticle hydrophobiticy, with the 
aim of controlling its phagocytic uptake during the first month after implantation.  
 
4. Conclusions 
 In this study, a PLGA microparticle formulation was developed that was 
compatible with intramyocardial injection in terms of particle size, injectability and 
tissue response. In addition, these particles exhibited the capacity to remain in the 
myocardium for up to three months. Concerning in vivo phagocytic uptake of 
microparticles, a moderate level of macrophage-mediated phagocytosis of PLGA 
microparticles was observed in the heart tissue. In particular, this result helps us to 
understand better the heart tissue response to a polymeric delivery system in the context 
of biomaterial research for cardiac regeneration.  
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Figure Captions 
 
Fig. 1. (A) Fluorescence image of representative 5 µm rhodamine loaded 
microparticles. Scale bars: 10 µm. (B) Scanning electron microscopy of representative 5 
µm PLGA microparticles prepared using TROMS. Scale bars: 8 µm. 
 
Fig. 2. Macroscopic view of the heart following 5 µm-sized PLGA microparticle 
implantation. Four days after LAD coronary artery occlusion, rats were anesthetized 
with isoflurane and ventilated. The chest was held opened by a retractor. Microparticles 
were injected into the infarct zone through a 29G needle while the heart was beating. 
Note the presence of the microparticles in the beating heart demonstrating that 
microparticles were not rapidly washed out from the infarcted myocardium. 
 
Fig. 3. Histological evaluation of myocardial tissue reaction 4 days after microparticle 
administration in hematoxylin-eosin stained sections. Microparticles with a diameter of 
2 µm (A, B) and 30 µm (C, D) are clearly visualized at high magnification (B, D 
indicated by arrows). Scale bars: 20 µm (A, C) and 100 µm (B, D). 
 
Fig 4. Biodegradation and tissue retention of 5 µm-sized fluorescent microparticles 
intramyocardially implanted in the infarcted heart 4 days after LAD coronary artery 
occlusion. Representative images of confocal microscopy (A, D) and hematoxylin eosin 
staining (B, C, E, F) of the peri-infarted area 1 and 3 months after PLGA microparticle 
(A, B, D, E) or resuspension media (control) (C, F) injection. The administration of 
microparticles was well tolerated by the tissue and no differences on tissue 
inflammation were found between the administration of medium or microparticles. Note 
that microparticles were still present in the peri-infarted area 3 months after the 
injection. Scale bars: 50 µm. 
 
Fig. 5. In vivo phagocytic uptake of 5 µm-sized PLGA microparticles. Representative 
pictures of CD68 (green) macrophage immunofluorescence of heart sections 1 week 
(A), 1 month (B) and 3 months (C) after intramyocardial administration of 
microparticles labeled with rhodamine (red). Nuclear staining was performed with 
TOPRO-3 (blue). Scale bars: 20 µm. Quantification of microparticle phagocytosis was 
determined as the ratio between rhodamine-loaded microparticles internalized into 
CD68-positive macrophage and the total number of microparticles detected in each 
section (D). ***P<0.001, **P<0.01. 
 
Graphical abstract. The administration of 5 µm-sized microparticles was well 
tolerated by the infarcted myocardium and no differences on tissue inflammation were 
found between the administration of medium or microparticles. Representative images 
of confocal microscopy (A, D) and hematoxylin eosin staining (B, C, E, F) of the peri-
infarted area 1 and 3 months after PLGA microparticle (A, B, D, E) or resuspension 
media (control) (C, F) injection. CD68 immunolabeling revealed 31%, 47% and below 
4% microparticle uptake by macrophages one week (G), one month (H) and three 
months (I) after injection respectively (P<0.001).  
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